Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Interchange of vaccine products, Lymphadenopathy, Vaccination site erythema, Vaccination site pain
Clinical narrative: 24 hour delayed swelling at injection site; Swollen lymph node in left armpit; Tenderness, itchiness, red spot at injection site; Itchiness, red spot at injection; Red spot at injection site; Dose 1 and Dose with Moderna COVID 19 vaccine; Dose 3 with Pfizer COVID 19 vaccine; Dose received 3; This is a spontaneous report received from a non-contactable reporter (Consumer or other non HCP). The reporter is the patient.   A 28-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 30Nov2021 at 17:00 (Lot number: FD0809) at the age of 28 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Hashimoto's disease" (unspecified if ongoing), notes: Hashimotos and "Gluten intolerance" (unspecified if ongoing), notes: Known allergies: Gluten. Concomitant medication included: SYNTHROID. Past drug history included: Morphine, reaction: "Drug allergy", notes: Known allergies: Morphine. Vaccination history included: Moderna covid-19 vaccine (DOSE 2, SINGLE, Lot number: 024M20A, Anatomical location: Left arm), administration date: 20Feb2021, when the patient was 28 years old, for COVID-19 immunisation and Moderna covid-19 vaccine (DOSE 1, SINGLE, Lot number: 037L20A, Anatomical location: Left arm), administration date: 21Jan2021, when the patient was 28 years old, for COVID-19 immunisation.  The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 30Nov2021 at 17:00, outcome "unknown", described as "Dose 1 and Dose with Moderna COVID 19 vaccine; Dose 3 with Pfizer COVID 19 vaccine"; IMMUNISATION (non-serious) with onset 30Nov2021 at 17:00, outcome "unknown", described as "Dose received 3"; VACCINATION SITE SWELLING (non-serious) with onset 01Dec2021, outcome "recovering", described as "24 hour delayed swelling at injection site"; LYMPHADENOPATHY (non-serious) with onset 01Dec2021, outcome "recovering", described as "Swollen lymph node in left armpit"; VACCINATION SITE PAIN (non-serious) with onset 01Dec2021, outcome "recovering", described as "Tenderness, itchiness, red spot at injection site"; VACCINATION SITE PRURITUS (non-serious) with onset 01Dec2021, outcome "recovering", described as "Itchiness, red spot at injection"; VACCINATION SITE ERYTHEMA (non-serious) with onset 01Dec2021, outcome "recovering", described as "Red spot at injection site". Therapeutic measures were not taken as a result of vaccination site swelling, lymphadenopathy, vaccination site pain, vaccination site pruritus and vaccination site erythema.  Additional Information: The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  No follow-up attempts are possible. No further information is expected.